Research programme: cannabis-based therapeutics - NEMUS Bioscience

Drug Profile

Research programme: cannabis-based therapeutics - NEMUS Bioscience

Alternative Names: Cannabidiol derivatives - NEMUS; Cannabionoid therapeutics - NEMUS; CBD derivatives - NEMUS; NB 1111; NB 1222; NB 2111; NB 2221; NB 2222; NB 23R1; NB 3111; NB 31R1; NB 51R1; NB3000 series; THC-valine-hemisuccinate; UM 5070

Latest Information Update: 18 May 2017

Price : $50

At a glance

  • Originator NEMUS Bioscience; University of Mississippi
  • Class Cannabinoids; Non-opioid analgesics
  • Mechanism of Action Cannabinoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Chemotherapy-induced nausea and vomiting; Methicillin-resistant Staphylococcus aureus infections; Muscle spasticity; Open-angle glaucoma; Pain; Peripheral nervous system diseases
  • Research Anxiety disorders; Diabetic retinopathy; Dry eyes; Epilepsy; Macular degeneration; Uveitis

Most Recent Events

  • 09 May 2017 Nemus Bioscience has patent protection for ocular delivery of THC-valine-hemisuccinate and other cannabinoid-based molecules in USA
  • 23 Mar 2017 Research programme: cannabis-based therapeutics - NEMUS Bioscience is available for licensing as of 03 Mar 2017.
  • 20 Mar 2017 Nemus Bioscience and Nanomerics enter into development agreement for the development of eye drop formulation of NB 1111 using Nanomerics' Molecular Envelope Technology (MET)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top